rts logo

Allogene Therapeutics Inc (ALLO) Stock Could Soon Reward Patient Investors


Allogene Therapeutics Inc (NASDAQ: ALLO) is 39.25% higher on its value in year-to-date trading and has touched a low of $2.23 and a high of $6.89 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ALLO stock was last observed hovering at around $4.46 in the last trading session, with the day’s gains setting it 0.01%.

Currently trading at $4.47, the stock is -6.68% and 2.58% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.38 million and changing 0.22% at the moment leaves the stock 15.58% off its SMA200. ALLO registered -9.15% loss for a year compared to 6-month gain of 31.86%. The firm has a 50-day simple moving average (SMA 50) of $4.23k and a 200-day simple moving average (SMA200) of -$1.34.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The stock witnessed a -12.70% loss in the last 1 month and extending the period to 3 months gives it a 39.69%, and is 2.05% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.61% over the week and 8.06% over the month.

Profit margin for the company is -202366.25%. Distance from 52-week low is 100.45% and -35.12% from its 52-week high. The company has generated returns on investments over the last 12 months (-48.10%).

Allogene Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.41 with sales reaching $10k over the same period.The EPS is expected to grow by 21.14% this year, but quarterly earnings will post -57.90% year-over-year. Quarterly sales are estimated to shrink -80.80% in year-over-year returns.

Allogene Therapeutics Inc (ALLO) Top Institutional Holders

243 institutions hold shares in Allogene Therapeutics Inc (ALLO), with institutional investors hold 95.13% of the company’s shares. The shares outstanding are 169.09M, and float is at 104.41M with Short Float at 26.58%. Institutions hold 73.78% of the Float.

The top institutional shareholder in the company is FMR, LLC with over 24.92 million shares valued at $123.84 million. The investor’s holdings represent 14.87% of the ALLO Shares outstanding. As of Jun 29, 2023, the second largest holder is TPG GP A, LLC with 18.72 million shares valued at $93.02 million to account for 11.17% of the shares outstanding. The other top investors are State Street Corporation which holds 8.48 million shares representing 5.06% and valued at over $42.14 million, while Blackrock Inc. holds 5.04% of the shares totaling 8.45 million with a market value of $41.98 million.

Allogene Therapeutics Inc (ALLO) Insider Activity

The most recent transaction is an insider purchase by Parker Geoffrey M.,the company’sCHIEF FINANCIAL OFFICER. SEC filings show that Parker Geoffrey M. bought 190 shares of the company’s common stock on Jan 30 ’24 at a price of $3.60 per share for a total of $683.0. Following the purchase, the insider now owns 0.82 million shares.

Allogene Therapeutics Inc disclosed in a document filed with the SEC on Dec 18 ’23 that MESSEMER DEBORAH M. (Director) sold a total of 18,640 shares of the company’s common stock. The trade occurred on Dec 18 ’23 and was made at $2.70 per share for $50317.0. Following the transaction, the insider now directly holds 62456.0 shares of the ALLO stock.

Still, SEC filings show that on Aug 07 ’23, Mayo Stephen (Director) disposed off 10,000 shares at an average price of $4.29 for $42855.0. The insider now directly holds 25,328 shares of Allogene Therapeutics Inc (ALLO).

Related Posts